



## Xenon to Report Q2 2025 Financial Results on August 11, 2025

August 4, 2025

VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, August 11, 2025.

### Conference Call/Webcast Information:

**Date:** Monday, August 11, 2025  
**Time:** 4:30 pm Eastern Time (1:30 pm Pacific Time)  
**Webcast:** [Pre-register here](#)  
**Dial-In:** (800) 715-9871 toll-free or (646) 307-1963 for international callers  
**Conference ID:** 4102397

A live webcast of the company presentation will be available on the [Investors](#) section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

### About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit [www.xenon-pharma.com](http://www.xenon-pharma.com).

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

### Contacts:

*For Investors:*

Chad Fugere  
Vice President, Investor Relations  
(857) 675-7275  
[investors@xenon-pharma.com](mailto:investors@xenon-pharma.com)

*For Media:*

Colleen Alabiso  
Senior Vice President, Corporate Affairs  
(617) 671-9238  
[media@xenon-pharma.com](mailto:media@xenon-pharma.com)



Source: Xenon Pharmaceuticals Inc.